G2GBIO Inc. (KOSDAQ:456160)

South Korea flag South Korea · Delayed Price · Currency is KRW
80,800
-8,200 (-9.21%)
At close: Dec 5, 2025
Market Cap 1.31T
Revenue n/a
Net Income n/a
Shares Out 16.26M
EPS n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 1,871,371
Average Volume 2,276,552
Open 89,000
Previous Close 89,000
Day's Range 80,100 - 90,200
52-Week Range 27,567 - 107,700
Beta n/a
RSI 51.30
Earnings Date n/a

About G2GBIO

G2GBIO Inc., a clinical-stage biotech company, provides pharmaceutical products. The company’s pipeline products includes GB-5001, GB-5001A, and GB-5112 for the treatment of alzheimer’s disease; GB-6002, an opioid drug that is used for post-operative pain treatment; GB-7001 for type-2 diabetes treatments; GB-5313 for the treatment of Osteoarthritis; GB-7101 and GB-7103 for the treatment of prostate cancer; GB-6201 and GB-6203 for androgenetic alopecia treatments; and GH-001 for the treatment of Hepatitis B. It also develops GB-2001 for animal c... [Read more]

Industry Pharmaceutical Preparations
Founded 2017
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 456160
Full Company Profile

News

There is no news available yet.